Empliciti

Chemical Nameelotuzumab
Dosage FormInjection (intravenous; 300 mg, 400mg)
Drug ClassMonoclonal antibodies
SystemBlood
CompanyBristol Myers Squibb
Approval Year2015

Indication

  • In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies.
  • In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Last updated on 10/19/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Empliciti (elotuzumab) Prescribing Information2019Bristol-Myers Squibb Company, Princeton, NJ